A Clinical Study for Children and Adults with Lennox-Gastaut Syndrome
The LGS DISCOVER study, also identified as the YKP509C003 study, is a clinical trial for pediatrics and adults with Lennox-Gastaut Syndrome (LGS).
The LGS DISCOVER study will evaluate whether an investigational medicine called carisbamate, when given along with other anti-seizure medications for epilepsy, can decrease the number of seizures in LGS patients 4-55 years of age who are on one or more anti-seizure medications.
Study Sites in the United States:
- Johns Hopkins Hospital, Baltimore, MD
- Duke University Clinical Research, Durham, NC
- Stanford University, Palo Alto, CA
- Children’s Hospital of Philadelphia, Philadelphia, PA
- Midatlantic Epilepsy and Sleep Center, Bethesda, MD
- Northeast Regional Epilepsy Group, Hackensack, NJ
- Pediatric Epilepsy and Neurology Specialists, Tampa, FL
For more information about the LGS DISCOVER study, please contact sklsicarisbamate@sklsi.com.
Additional Information:
View the LGS DISCOVER Study Brochure
Visit the LGS DISCOVER Study Website
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.
Updated 06/05/26 (AM)